NCT06417450Completed
Usefulness of NESA Microcurrents in the Treatment of Children With Autism Spectrum Disorders
Utility of NESA Microcurrents in the Treatment of Sleep Disturbances, Disruptive Behaviours of Children With Autism Spectrum Disorders and in the Quality of Life of the Family Unit.
Source: ClinicalTrials.gov · Last updated 22 Aug 2025
Brief summary (registry, in English)
The term or definition of Autism Spectrum Disorder (ASD) defines a pervasive neurodevelopmental disorder in which deficits in communication and social interaction, altered sensorimotor behaviours, repetitive, restricted and stereotyped interests and activities are observed. One of the disorders most frequently associated with ASD, and which most affects the quality of life of the child and his or her family, is sleep disorders; it is estimated that between 50 and 80 percent of children with ASD present this alteration and generally continue to suffer from it in adolescence and adulthood; It has also been observed that there is a correlation between sleep problems and an increase in aggressive behaviour, social and emotional deficits and deficits in activities of daily living, which severely affects the child and his or her close family environment; they become emotionally destabilised in a notorious way, and this has a negative impact on their work and productive environment. The microcurrents generated by the non-invasive neuromodulation device introduce, by means of a non-invasive technique (surface electrodes), electrical energy to normalise the nervous stimulus. This makes it an excellent complementary treatment to the activity of rehabilitation treatment. Its effects are achieved by establishing several input nerve pathways corresponding to the body's dermis, through which the signals are intellectualised in time-space. These signals are the basis for achieving normalisation of the nerve impulse by means of microcurrents.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 40 (actual)
- First submitted
- 13 May 2024
- Start date
- 13 May 2024
- Primary completion date
- 13 May 2025
- Lead sponsor
- University of Las Palmas de Gran Canaria
- Diseases
- Autism
- NCT number
- NCT06417450
What you commit to
- Study type: Interventional
- Participants enrolled: 40
- From 13 May 2024 to the primary completion date, 13 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Present some of the contraindications for treatment with NESA XSIGNAL®: pacemakers, internal haemorrhages, not applying electrodes on skin in poor condition, with ulcerations or wounds, acute febrile processes, acute thrombophlebitis and/or phobia of electricity.
Other
- If parents do not sign the informed consent form.
- Presence of uncontrolled convulsions.
Who the study is looking for
- Children with a diagnosis of Autistic Spectrum Disorder, attending school in the City of San Juan de Dios in Las Palmas de Gran Canaria.
- Children with symptoms related to sleep disturbances.
- Children who present episodes of disruptive behaviour.
- Children who may present sensory alterations or cognitive deficits.
- Children whose parents sign the informed consent form.
Age in the registry: 2 years to 18 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Las Palmas de Gran Canaria Coordinator of this site? Confirm its status | Las Palmas de Gran Canaria | Spain | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.